DaVita Inc. $DVA Holdings Raised by Epoch Investment Partners Inc.

Key Points

• Epoch Investment Partners Inc. increased its stake in DaVita Inc. by 10.7% during the first quarter, owning about 0.53% of the company with a valuation of $62.4 million.
• DaVita's quarterly earnings exceeded analysts' expectations with $2.95 earnings per share, up from $2.00 in the same quarter last year, while revenue rose by 6.1% year-over-year.
• DaVita has recently been rated by analysts with mixed signals: Truist set a target price of $148.00, while Barclays reduced their price target from $169.00 to $160.00.

Epoch Investment Partners Inc. increased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 10.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 407,921 shares of the company's stock after purchasing an additional 39,485 shares during the quarter. Epoch Investment Partners Inc. owned about 0.53% of DaVita worth $62,400,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. UMB Bank n.a. lifted its stake in shares of DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after acquiring an additional 76 shares during the period. National Pension Service raised its holdings in DaVita by 74.3% during the first quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after purchasing an additional 84 shares in the last quarter. Copia Wealth Management acquired a new stake in DaVita in the fourth quarter worth approximately $30,000. Y.D. More Investments Ltd bought a new position in DaVita during the 1st quarter valued at $35,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new position in shares of DaVita during the 1st quarter valued at $83,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Insider Activity

In related news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by corporate insiders.

DaVita Trading Up 0.9%

Shares of NYSE DVA opened at $138.62 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60. The company has a market cap of $9.91 billion, a price-to-earnings ratio of 13.63, a P/E/G ratio of 0.98 and a beta of 1.09. The business has a fifty day simple moving average of $139.66 and a 200-day simple moving average of $143.41.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. During the same quarter last year, the business posted $2.00 EPS. DaVita's revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on DVA shares. Truist Financial set a $148.00 target price on DaVita in a research note on Friday, August 8th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, August 22nd. Finally, Barclays lowered their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, DaVita currently has an average rating of "Hold" and a consensus target price of $164.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.